We showed novel evidence on the inhibitory effects of LAS194046, a recent developed pan-JAK inhibitor, on activated neutrophils from severe asthma and COPD patients, reducing IL-8 and MMP9 secretion and superoxide anion generation, as well as improving the impaired anti-inflammatory effects of corticosteroids in neutrophils from severe asthma and COPD patients. This evidence concerns the gene MMP9 and asthma.